In a study published in the Journal of clinical oncology, Oral #SERD, #Elacestrant significantly improved PFS compared to standard of...

On November 8, 2022, the FDA approved cemiplimab-rwlc in combination with platinum-based chemotherapy as first line therapy for patients with...

In phase III NEOPAN study presented by Dr. Ducreux, FOLFIRINOX improved progression-free survival (PFS) compared to gemcitabine in #locally_advanced unresectable...

In a multicentre, single-arm, phase 2 trial conducted by MD Anderson Cancer Center, carefully selected early stage #TNBC or #HER2...

In COSMIC-312 trial, first line #Cabozantinib plus #atezolizumab improved PFS versus #sorafenib for patients with advanced HCC. In this phase...

On Sept 8, 2022, the #FDA issued a safety communication to highlight reports of squamous cell carcinoma and various #lymphomas...

The addition of stereotactic body radiation therapy (SBRT) to sorafenib for patients with hepatocellular carcinoma (HCC) improved PFS and OS...

The results of the exploratory analysis from POSEIDON trial were presented by Dr. Melissa Johnson. In this phase III trial,...

ADT Intensification might be the resort to delay biochemical progression in High risk biochemical relapse (BCR) #prostate cancer after Radical...

The #FDA has approved Tremelimumab plus Durvalumab for patients with unresectable #Hepatocellular Carcinoma. This approval was based on the results...